Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Low-profile biotech gets $30M, new CEO and new home for PhIII atrial fib effort

A low-profile biotech in Cleveland landed a $30 million B round with the help of a new group of prominent venture backers and has been given a new CEO, a new home in La Jolla and a continuing mission to develop a drug for atrial fibrillation that has quietly moved to the threshold of a Phase III program.

Glaxo's Connelly bows out amid scramble to turn around U.S. business

GlaxoSmithKline's sputtering U.S. sales gave the company a black eye with investors. Now, the company's U.S. chief is stepping down. Deirdre Connelly is out the door, the company told employees on Tuesday, with SVP Jack Bailey rising to take her place.

Le Figaro: Sanofi will tap Bayer's Brandicourt as CEO this week

Olivier Brandicourt is the man. Sanofi will officially hand the reins to Brandicourt this week, Le Figaro reports, ending months of speculation about the French drugmaker's new CEO. Now heading up Bayer HealthCare, Brandicourt has reportedly been on Sanofi's short list since ex-CEO Chris Viehbacher made his untimely exit--or perhaps before.

Otsuka appoints new president to replace Taro Iwamoto, who died of heart failure

SINGAPORE-- On Feb. 11, Otsuka Pharmaceutical appointed a new president, Tatsuo Higuchi, already president and CEO of the parent holding company, to replace Taro Iwamoto, who died two days earlier.

Bayer's Brandicourt said to top Sanofi CEO list: Bloomberg

Sanofi Chairman Serge Weinberg recently brushed away suggestions that the French drugmaker was having a hard time finding someone who wanted to be CEO of the company. Now the talk is that Bayer's Olivier Brandicourt, who is also a Pfizer alum, is the top contender.

Dennis Gillings to step down as Quintiles chairman

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Glaxo layoffs continue as 27 Montana vaccine workers get the ax

GlaxoSmithKline's job-chopping ax has struck Hamilton, MT, where 27 vaccine researchers will pack up this year. The pharma giant plans to centralize its R&D efforts in one location, but where that will be hasn't yet been decided, company spokeswoman Melinda Stubbee told local paper  Missoulian.

FDA Commissioner Margaret Hamburg to step down

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

With Pfizer set to buy Hospira, what's in the future for CEO F. Michael Ball?

In four years as CEO of Hospira, F. Michael Ball has moved the company from its quality quagmire and a stock price collapse to an injectable drug leader and biosimilar player significant enough to be a prize worthy of a $15 billion buyout offer from Pfizer. People who make predictions about these kinds of things say Ball's rehab of Hospira would make him in big demand to run another company in need of a makeover.

Look for a new Sanofi CEO by March, says chairman, as earnings top forecast

Striking out in our CEO search? Not us, says Sanofi. Chairman Serge Weinberg says the board is talking to a "limited number of candidates" and expects to make a choice very soon. A choice, by the way, from outside Sanofi, Weinberg says.